Skip to main content
Full access
Letter to the Editor
Published Online: 1 March 1999

Combination Treatment With Venlafaxine and Bupropion

Publication: American Journal of Psychiatry
To the Editor: We describe an apparent antidepressant response to a combination of venlafaxine and bupropion, despite previous unsuccessful trials of each agent alone.
Ms. A, a 42-year-old white woman, presented with dysthymia and major depression that had been successfully treated with fluoxetine, 15 mg/day, for 5 years. Fluoxetine induced sexual dysfunction, which led to attempts to substitute other antidepressants as follows: sertraline, 75 mg/day for 4 weeks; paroxetine, 30 mg/day for 6 weeks; bupropion, 75 mg/day for 4 weeks; and venlafaxine, 75 mg/day for 8 weeks. There were no therapeutic responses to these trials, and adverse drug reactions prompted a return to fluoxetine. For instance, bupropion caused agitation, and venlafaxine induced headaches, sedation, and sexual dysfunction. Ms. A then elected a trial without medication. Three months later, a moderate to severe major depression began and developed over 4 months. Nefazodone, up to 500 mg/day, was taken over 10 weeks but was discontinued because of lack of response. Next, bupropion was retried and increased over 7 weeks up to 225 mg/day. After 3 weeks at this dose, no improvement was seen, and severe urinary urgency developed as an adverse drug reaction. Therefore, bupropion was tapered to 187.5 mg/day and venlafaxine, 12.5 mg/day, was added. Seven days after this addition and 5 months after the onset of the major depression, symptoms improved. Full remission was achieved after 2 weeks of the combination, with final daily doses of bupropion being 187.5 mg and venlafaxine being 37.5 mg. The depression has been in remission for 14 months, and adverse drug reactions have not been a problem.
The combination of selective serotonin reuptake inhibitors with bupropion has been reported by others (1). To our knowledge, this is the first description of the combination of a serotonin-norepinephrine reuptake inhibitor, venlafaxine, with bupropion. Because the proposed mechanism of action of bupropion is dopaminergic and noradrenergic (2), one strategy for the treatment of refractory depression would be the addition of a serotonergic antidepressant to the bupropion regimen. A combination of drugs affecting multiple neurotransmitters may be more effective in some cases. In addition, the combination of drugs may allow for an antidepressant response at lower doses, which, as in our case, might avoid the unacceptable side effects seen at higher doses. Although no adverse interactions were apparent in our case, including the absence of hypertension, combining these drugs is not necessarily a benign strategy.

References

1.
Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ: Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997; 58:137–145
2.
Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F: Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56:395–401

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 494
PubMed: 10080572

History

Published online: 1 March 1999
Published in print: March 1999

Authors

Details

MICHAEL A. KIRSCH, M.D.
ALAN K. LOUIE, M.D.
San Francisco, Calif.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share